司库奇尤单抗治疗银屑病的真实世界证据:43项研究的荟萃分析
该荟萃分析纳入43项真实世界研究,评估司库奇尤单抗治疗中重度斑块状银屑病的有效性、药物留存率和安全性。结果显示12个月药物留存率80%,PASI 90/100应答率分别为60%和51%,DLQI 0/1达65%,安全性与临床试验一致。
要点
- 司库奇尤单抗12个月药物留存率80%,因疗效不佳停药者仅8%。
- 12个月PASI 90和PASI 100应答率分别为60%和51%。
- 12个月65%患者DLQI达0或1,安全性与临床试验一致。
核心结论
- 司库奇尤单抗治疗中重度斑块状银屑病具有高药物留存率、高患者报告结局和良好耐受性。
研究设计与样本
- 检索Embase和ClinicalTrials.gov(2015年1月1日至2019年5月31日),纳入43项真实世界研究及对照研究中的司库奇尤单抗组。
- 使用R统计软件meta包分析,在3、6、12个月评估关键结局。
主要发现
- 药物留存率在3个月和6个月为90%,12个月为80%。
- 12个月时8%患者因缺乏疗效停药。
- 3、6、12个月PASI 90分别为50%、53%、60%,PASI 100分别为36%、46%、51%。
- 3、6、12个月DLQI 0/1分别为57%、55%、65%。
- 不良事件发生率与临床试验一致,无新安全信号。
临床怎么用
- 真实世界数据支持司库奇尤单抗用于中重度斑块状银屑病的长期治疗。
- 高药物留存率和DLQI改善提示患者依从性和生活质量获益良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Real-world evidence (RWE) meta-analyses provide valuable insights from patients in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that neutralizes IL-17A, has shown long-lasting effectiveness and safety in plaque psoriasis (PsO). Since its licence approval in 2015, many RWE studies have been published. The objective of this study was to review all available literature on RWE studies with secukinumab and the secukinumab arm of comparator studies in patients with moderate-to-severe PsO to evaluate its effectiveness, drug survival and safety. https://www.embase.com and https://clinicaltrials.gov databases were searched using prespecified inclusion criteria between 1 January 2015 and 31 May 2019. Using a meta-package and R statistical software to analyse data, key outcomes were measured at 3, 6 and 12 months. PASI and DLQI score data were recorded for patients who remained on secukinumab treatment. Overall, 43 studies were included. Drug survival was 90% at 3 and 6 months, and 80% at 12 months. At 12 months, 8% of patients had discontinued treatment due to lack of effectiveness. At 3, 6 and 12 months, Psoriasis Area and Severity Index (PASI) 90 scores were as follows: 50%, 53% and 60%, and PASI 100 scores were 36%, 46% and 51%, respectively. At 3, 6 and 12 months, 57%, 55% and 65% of patients achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1, respectively. Adverse events were consistent with rates observed in clinical trials with no new safety signals. This meta-analysis strengthens existing evidence on the clinical effectiveness of secukinumab in patients with moderate-to-severe PsO, demonstrating high drug survival rates, high levels of patient-reported outcomes, and good tolerance.
引用
- Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020. PMID: 31919937. doi:10.1111/jdv.16180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。